Piramal Pharma Ltd. (PPLPHARMA): Piramal Pharma Share Price Rises 3.51% as Stock Emerges Among Top Gainers Today

Piramal Pharma Ltd. traded at Rs 216.9, up 3.51% today, taking its market capitalisation to Rs 28,031.53 crore and placing the stock among notable gainers.

Piramal Pharma Share Price was at Rs 216.9 on 20 August 2026 at 3:23:17 PM IST, up Rs 7.35 or 3.51% from the previous close of Rs 209.55. With a market capitalisation of Rs 28,031.53 crore, the company sits in the Large Cap category, which makes today’s price rise notable in the context of Stock Market Today and the wider Indian Stock Market. The move also brought Piramal Pharma Share Price Today into focus across both NSE and BSE tracking screens, even though the supplied data confirms the price event rather than a company-specific catalyst.

From the session data, the stock opened at Rs 209.95, touched an intraday high of Rs 216.9 and did not move below Rs 209.55, which was also the day’s low and the previous close. That pattern shows that the session strength built after the open and held into the later part of trade. Total traded volume stood at 42,15,323 shares, including 39,60,957 shares on NSE and 2,54,366 shares on BSE, while turnover on the exchange cited in the data was Rs 5.52 crore.

For readers looking for Piramal Pharma Stock News, the main verified takeaway is straightforward: this was a meaningful same-day share price gain in a large-cap healthcare name. In this Univest report, the focus is on what today’s move says about price action, how Piramal Pharma Share Price compares with the broader Healthcare benchmark, and why investors may continue to monitor the stock without turning that into a recommendation or forecast.

Piramal Pharma Ltd. (PPLPHARMA) Share Price Today: Price Action Analysis

Piramal Pharma Ltd. (PPLPHARMA) traded at Rs 216.9. versus the previous close of Rs 209.55, a rise of 3.51%. The stock opened at Rs 209.95, reached Rs 216.9, touched Rs 209.55. Reported volume was 2,54,366.

Piramal Pharma Ltd. (PPLPHARMA) Fundamental Analysis

Piramal Pharma Fundamental Analysis in the supplied data starts with scale. The company’s market capitalisation is Rs 28,031.53 crore, which clearly places it in the large-cap bracket and makes it much larger than the healthcare benchmark universe figures listed in the sector snapshot. Market capitalisation by itself does not indicate quality or valuation, but it does show that Piramal Pharma is materially larger than the median and average companies in the same sector dataset.

The broader Healthcare benchmark contains 196 companies. Within that benchmark, the median market capitalisation is Rs 135.91 crore and the average is Rs 467.67 crore, while the maximum company size shown is Rs 3,012.78 crore. Against that backdrop, Piramal Pharma Share Price is attached to a company whose market value is far above the benchmark’s median, average and even maximum listed benchmark company. That gap is one of the clearest fundamental context points in this Univest stock analysis: investors are not looking at a small, thinly capitalised counter, but at a significantly larger listed healthcare company.

The valuation and profitability side is more limited because company-specific P/E, P/B, ROE, ROCE, EPS, book value, dividend yield, leverage and cash-flow figures are not part of the supplied company snapshot. Even so, the absence of those numbers in the company block does not change the importance of the size comparison already visible in the data. For Piramal Pharma Share Price News, that means today’s rise is being assessed primarily through market value, trading action and sector positioning rather than through a fresh valuation rerating signal confirmed by the dataset.

What supports investor attention here is the combination of a meaningful same-day gain and a large market capitalisation within Healthcare. What still needs monitoring is whether later disclosures, financial results or company news provide a clearer business-level explanation for the move. For now, the factual reading from Univest is that price action has turned the stock into a market conversation point, while the next layer of interpretation comes from sector and peer comparison.

Sector and Industry Context

Piramal Pharma Ltd. (PPLPHARMA) is classified under sector: Healthcare.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Piramal Pharma Share Price is moving within the Healthcare sector, and the supplied benchmark data offers useful context on how this universe is valued and how broad it is. The benchmark scope is defined as the same sector and covers 196 companies, making it a wide comparison set rather than a narrow basket. That matters because a price rise in a large-cap healthcare stock has to be viewed against a sector where valuation and profitability figures vary significantly across companies.

Within this Healthcare benchmark, the median P/E is 26.32 and the average P/E is 61.3, based on 157 companies. The range is exceptionally wide, from 2.76 to 1,607.56, which indicates that sector valuations are dispersed and can be influenced by business mix, earnings volatility or loss-making companies. On price-to-book, 195 companies produce a median of 1.9 and an average of 2.61, with values ranging from -13.33 to 16.47. Profitability also spans a wide range: the median ROE is 11.12 and average ROE is 15.66 across 195 companies, while median ROCE is 13.35 and average ROCE is 17.87.

The size profile of the same sector is equally striking. The median market capitalisation is Rs 135.91 crore and the average is Rs 467.67 crore, while the maximum benchmark company is Rs 3,012.78 crore. Piramal Pharma, at Rs 28,031.53 crore, sits far above that reference range, which immediately sets it apart in terms of scale within the supplied Healthcare snapshot. In practical terms, Piramal Pharma Share Price is being tracked as a large-cap healthcare move in a sector where many constituents are much smaller and spread across different valuation bands.

For readers following Healthcare names on Univest, the sector takeaway is clear: today’s price rise did not happen in a homogeneous space. It happened in a broad sector with highly varied P/E, P/B, ROE and ROCE levels. That makes peer positioning important, because direct comparisons can often say more than sector averages alone.

Peer Comparison

Piramal Pharma Ltd. (PPLPHARMA) has a market capitalisation of Rs 28,031.53 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Piramal Pharma Share Price can also be assessed by comparing market value with the listed peers supplied in the dataset. The peer set includes Ind-Swift Laboratories, Hikal, Dishman Carbogen Amcis, Solara Active Pharma Sciences, Beta Drugs, Dr Agarwals Eye Hospital, Panacea Biotec, Venus Remedies, Sai Parenteral’s and Fredun Pharmaceuticals. Most of these peers fall within Pharmaceuticals & Drugs, while Dr Agarwals Eye Hospital represents Hospital & Healthcare Services.

The first and most obvious difference is scale. Piramal Pharma’s market capitalisation of Rs 28,031.53 crore is far above Ind-Swift Laboratories at Rs 3,012.78 crore, Hikal at Rs 2,679.94 crore, Dishman Carbogen Amcis at Rs 2,648.85 crore, Solara at Rs 2,641.96 crore and Beta Drugs at Rs 2,610.72 crore. Even the largest peer in the list is only a fraction of Piramal Pharma’s size. That makes Piramal Pharma Share Price distinctive within this peer set because investors are dealing with a much larger listed entity than the directly supplied comparables.

On valuation and profitability, the peer numbers underline how mixed Healthcare can be. Ind-Swift trades at a P/E of 48.9 with ROE of -0.78 and ROCE of 8.31. Dishman Carbogen Amcis is at a P/E of 167.12 with ROE of -2.89 and ROCE of -0.26. Beta Drugs shows a P/E of 64.32, P/B of 10.17, ROE of 18.65 and ROCE of 22.17. Dr Agarwals Eye Hospital has a P/E of 33.71, P/B of 6.95, ROE of 36.29 and ROCE of 42.4, the strongest profitability combination in this peer block. Venus Remedies trades at a P/E of 20.4 with ROE of 9.85 and ROCE of 7.89.

Because company-specific P/E, P/B, ROE and ROCE for Piramal Pharma are not part of the supplied dataset, the cleanest peer conclusion is based on market-cap positioning and the diversity of peer fundamentals. In Univest coverage terms, Piramal Pharma Share Price stands out less for a directly comparable valuation read and more for its far larger scale than the available peers. That can influence how the market interprets a same-day price rise, especially when a large-cap stock becomes a top gainer in a mixed sector.

Why Investors Are Watching Piramal Pharma

Piramal Pharma Share Price is being watched because today’s move combines a visible price rise, a close near the day’s high and a large-cap market value in a broad Healthcare universe. The supplied data confirms strong same-day market action, even though it does not establish a company-specific trigger. That is enough to place the stock firmly on the watchlist for traders and long-term market observers tracking Stocks in News and Market Movers.

• Verified price action: the stock rose 3.51% to Rs 216.9 from Rs 209.55.
• Session structure: the day low matched the previous close at Rs 209.55, while the day high was Rs 216.9.
• Volume profile: total traded volume reached 42,15,323 shares across NSE and BSE.
• Large-cap context: market capitalisation stood at Rs 28,031.53 crore.
• Sector position: the move came inside a Healthcare benchmark spanning 196 companies.
• Peer scale: the company’s market value is much larger than each supplied peer.

The next things investors may monitor are whether Piramal Pharma Share Price holds above today’s breakout zone in subsequent sessions, whether volume participation remains elevated, and whether future company news, earnings or financial results offer a clearer explanation for the move. Univest would frame this as a stock worth tracking for follow-through, not as a conclusion about future direction.

About Piramal Pharma

Piramal Pharma Ltd. is the listed company under focus in this price-rise update. The supplied dataset places it within the Healthcare sector, which is the key verified business classification available for this article. That means Piramal Pharma Share Price is being analysed in the context of one of the largest and most diverse segments of the Indian stock market, where benchmark companies span Pharmaceuticals & Drugs as well as Hospital & Healthcare Services.

The sector data also shows how broad that universe is. The benchmark includes 196 companies, with valuation and profitability metrics spread across wide ranges. Within that setting, Piramal Pharma stands out in one clearly measurable way: scale. At Rs 28,031.53 crore in market capitalisation, it is much larger than the median and average Healthcare company in the supplied benchmark and also well above the market-cap figures of the peers listed alongside it.

For readers using this as Piramal Pharma Company News or Piramal Pharma Share News, the important factual point is that the stock belongs to a sector where both valuations and returns vary sharply from company to company. That makes market-cap strength and trading behaviour especially relevant when the stock enters Top Gainers Today lists. On Univest, this kind of context helps investors place Piramal Pharma Share Price within the broader Healthcare landscape without stretching beyond the verified data provided here.

Track Piramal Pharma Share Price on Univest

Use Piramal Pharma Ltd. (PPLPHARMA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to keep following Piramal Pharma Share Price can use Univest to monitor live share price moves, daily percentage changes, market capitalisation, 52-week levels, technical indicators where available, valuation ratios, sector comparisons and shareholding pattern updates when disclosed. Piramal Pharma Share Price Today has already shown how quickly a large-cap healthcare stock can move into the market spotlight.

Univest also helps users compare stocks across NSE and BSE, review peer metrics, and place daily price action inside a wider market and sector framework. For readers tracking Piramal Pharma Latest News, Piramal Pharma Stock Performance and Piramal Pharma Share Price Update, that ongoing context is often as important as the one-day move itself.

Frequently Asked Questions

Why is Piramal Pharma Share Price rising today?

Ans. Piramal Pharma Share Price rose because the stock gained Rs 7.35, or 3.51%, in the current session to Rs 216.9. The supplied data confirms the market move and strong session price action, but it does not establish a company-specific catalyst.

What is Piramal Pharma Share Price Today?

Ans. Piramal Pharma Share Price Today was Rs 216.9 at 3:23:17 PM IST on 20 August 2026. That was up from the previous close of Rs 209.55, translating into a one-day gain of 3.51% or Rs 7.35.

How much did Piramal Pharma stock gain in today’s trade?

Ans. Piramal Pharma stock gained 3.51% in today’s session. In absolute terms, the share price rose by Rs 7.35, moving from the previous close of Rs 209.55 to Rs 216.9 during the trading day.

What were the day high and day low for Piramal Pharma shares?

Ans. Piramal Pharma touched a day high of Rs 216.9 and a day low of Rs 209.55. The low matched the previous close, while the stock later advanced to the session high, showing sustained intraday strength.

What was the opening price of Piramal Pharma today?

Ans. Piramal Pharma opened at Rs 209.95 today, only slightly above the previous close of Rs 209.55. From there, the stock moved higher through the session and eventually reached an intraday high of Rs 216.9.

What is the market capitalisation of Piramal Pharma?

Ans. Piramal Pharma’s market capitalisation stood at Rs 28,031.53 crore in the supplied data. That places the company in the Large Cap category and makes it significantly bigger than the median Healthcare company in the benchmark snapshot.

How much volume was traded in Piramal Pharma shares today?

Ans. Total traded volume in Piramal Pharma shares was 42,15,323. This included 39,60,957 shares on NSE and 2,54,366 shares on BSE, showing that most of the day’s activity came from NSE participation.

What was the turnover reported for Piramal Pharma today?

Ans. The supplied data shows turnover of Rs 5.52 crore for Piramal Pharma on the cited exchange. Alongside the day’s 3.51% gain and total volume of 42,15,323 shares, it confirms active market participation.

How does Piramal Pharma compare with the Healthcare sector by size?

Ans. Piramal Pharma is far larger than the Healthcare benchmark averages in the supplied dataset. Its market capitalisation is Rs 28,031.53 crore, versus a sector median of Rs 135.91 crore and average of Rs 467.67 crore.

Why are investors watching Piramal Pharma after today’s move?

Ans. Investors are watching Piramal Pharma because it is a large-cap Healthcare stock that rose 3.51% and closed near the day’s high at Rs 216.9. The move also came with total traded volume of 42,15,323 shares.